IRIS
VITALE, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.203
EU - Europa 9.790
AS - Asia 4.687
SA - Sud America 1.081
AF - Africa 124
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 6
Totale 26.906
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.077
GB - Regno Unito 2.667
RU - Federazione Russa 2.031
CN - Cina 1.674
IT - Italia 1.641
SG - Singapore 1.437
IE - Irlanda 988
BR - Brasile 914
UA - Ucraina 590
SE - Svezia 541
HK - Hong Kong 427
DE - Germania 410
VN - Vietnam 346
FR - Francia 335
KR - Corea 295
FI - Finlandia 247
IN - India 126
NL - Olanda 92
TR - Turchia 70
AR - Argentina 60
BD - Bangladesh 55
PL - Polonia 53
CA - Canada 52
MX - Messico 49
JP - Giappone 37
PK - Pakistan 37
IQ - Iraq 34
ES - Italia 31
EC - Ecuador 30
CZ - Repubblica Ceca 29
BE - Belgio 28
ZA - Sudafrica 25
AT - Austria 24
CI - Costa d'Avorio 23
SA - Arabia Saudita 19
ID - Indonesia 18
MA - Marocco 17
VE - Venezuela 16
KE - Kenya 14
PE - Perù 14
UZ - Uzbekistan 14
CL - Cile 13
IR - Iran 13
AU - Australia 12
CO - Colombia 12
DZ - Algeria 12
AE - Emirati Arabi Uniti 11
CH - Svizzera 11
JO - Giordania 10
EG - Egitto 9
LT - Lituania 9
TN - Tunisia 9
UY - Uruguay 9
BY - Bielorussia 8
GR - Grecia 8
IL - Israele 7
PY - Paraguay 7
JM - Giamaica 6
KZ - Kazakistan 6
LB - Libano 6
MY - Malesia 6
AL - Albania 5
DK - Danimarca 5
EU - Europa 5
HU - Ungheria 5
NP - Nepal 5
RS - Serbia 5
TT - Trinidad e Tobago 5
BH - Bahrain 4
BO - Bolivia 4
PA - Panama 4
PT - Portogallo 4
SN - Senegal 4
AO - Angola 3
AZ - Azerbaigian 3
BA - Bosnia-Erzegovina 3
BG - Bulgaria 3
CR - Costa Rica 3
ET - Etiopia 3
LV - Lettonia 3
NO - Norvegia 3
OM - Oman 3
PS - Palestinian Territory 3
RO - Romania 3
AM - Armenia 2
CY - Cipro 2
DO - Repubblica Dominicana 2
GY - Guiana 2
HN - Honduras 2
KG - Kirghizistan 2
KW - Kuwait 2
LA - Repubblica Popolare Democratica del Laos 2
LU - Lussemburgo 2
NZ - Nuova Zelanda 2
PH - Filippine 2
SK - Slovacchia (Repubblica Slovacca) 2
TM - Turkmenistan 2
TW - Taiwan 2
BN - Brunei Darussalam 1
BW - Botswana 1
Totale 26.889
Salva come PNG Salva come JPEG
Città #
Southend 2.461
Dallas 1.820
Fairfield 1.216
Dublin 974
Singapore 869
Ashburn 820
Santa Clara 614
Moscow 568
Woodbridge 567
Jacksonville 475
Wilmington 470
Seattle 466
Chandler 463
Houston 459
Hong Kong 421
Cambridge 420
Beijing 406
Siena 354
Hefei 336
Ann Arbor 327
Menlo Park 319
Seoul 293
Princeton 234
New York 217
Milan 171
Nanjing 153
Los Angeles 147
Helsinki 112
Rome 112
The Dalles 101
Ho Chi Minh City 98
Munich 97
San Mateo 87
São Paulo 78
San Diego 74
Dong Ket 73
Dearborn 72
Buffalo 67
Hanoi 67
Boardman 65
Nanchang 58
Bengaluru 54
Düsseldorf 51
Council Bluffs 50
Florence 48
Redondo Beach 47
Columbus 46
Shenyang 45
Shanghai 36
Lauterbourg 34
London 34
Tianjin 32
Warsaw 31
Chicago 30
Lappeenranta 30
Nuremberg 29
Changsha 28
Guangzhou 28
Rio de Janeiro 28
Washington 28
Izmir 27
Jiaxing 27
Turku 27
Bologna 26
Tokyo 26
Brooklyn 25
Hebei 25
Orem 25
Brussels 24
Abidjan 23
Mexico City 22
San Francisco 22
Turin 22
Norwalk 21
Olomouc 21
Portsmouth 21
Jinan 20
Kraków 20
Denver 19
Belo Horizonte 18
Kunming 18
Atlanta 17
Frankfurt am Main 17
San Jose 17
Amsterdam 16
Phoenix 16
Stockholm 16
Boston 15
Campinas 15
Johannesburg 15
Perugia 15
Bari 14
Da Nang 14
Naples 14
Chennai 13
Manchester 13
Padova 13
Poplar 13
Redwood City 13
Ankara 12
Totale 18.667
Salva come PNG Salva come JPEG
Nome #
VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases 804
A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study 377
A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome 333
Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: A four-year follow-up study 330
Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis 300
Ten-Year Retention Rate of Infliximab in Patients with Behçet’s Disease-Related Uveitis 300
Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study 299
Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients 298
Auditory involvement in Behcet’s disease: relationship with demographic, clinical, and therapeutic characteristics 288
Biological treatments: new weapons in the management of monogenic autoinflammatory disorders 280
A case of resistant adult-onset periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) syndrome responsive to anakinra. 269
Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies 265
Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis 254
Quality of life impairment in Behçet’s disease and relationship with disease activity: a prospective study 253
The diagnostic evaluation of patients with a suspected hereditary periodic fever syndrome: experience from a referral center in Italy 249
Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet’s syndrome 245
Challenges and new horizons in the periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome 243
Certolizumab Pegol treatment in Behcet’s disease with different organ involvement: a multicenter retrospective observational study 240
Behçet’s syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics 240
Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behçet’s Disease 231
Weekly oral alendronate in mevalonate kinase deficiency 230
The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease 226
Efficacy and Safety of Adalimumab in Behçet’s disease related uveitis: a multicenter retrospective observational study 222
Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab 221
Correlation of Serum Amyloid-A Levels, Clinical Manifestations, Treatment, and Disease Activity in Patients with Behçet's Disease 221
Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study 220
Systemic Steroid Sparing Effect of Intravitreal Dexamethasone Implant in Chronic Noninfectious Uveitic Macular Edema 218
Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases: Response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–1683 217
Adalimumab-Based Treatment Versus Disease-Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome: A Retrospective Study of Seventy Patients With Vascular Involvement 215
Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: An observational multicentre study 214
Impact of Uveitis on Quality of Life: A Prospective Study from a Tertiary Referral Rheumatology-Ophthalmology Collaborative Uveitis Center in Italy 214
Immunometabolic biomarkers of inflammation in Behçet's disease: Relationship with epidemiological profile, disease activity and therapeutic regimes 207
The eye involvement in monogenic autoinflammatory diseases: Literature review and update 207
Childhood versus adulthood-onset autoinflammatory disorders: myths and truths intertwined 205
Clinical and biochemical landmarks in systemic autoinflammatory diseases 204
Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study 204
Working the endless puzzle of hereditary autoinflammatory disorders. 203
Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature 201
Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet’s disease 198
Critical regulation of Th17 cell differentiation by serum amyloid-A signalling in Behcet's disease 196
A patient-driven registry on Behçet’s disease: the AIDA for patients pilot project 195
Diagnostic criteria for adult-onset periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome 194
The diagnostic evaluation of patients with potential adult-onset autoinflammatory disorders: our experience and review of the literature 194
Anakinra long-term efficacy and safety in the management of Schnitzler's syndrome and latent tuberculosis infection 190
Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease 184
Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with Behçet's disease 180
The hereditary autoinflammatory disorders uncovered 179
Coexistence of axial spondyloarthritis and thromboangiitis obliterans in a young woman 179
Long-Term Outcomes of Behçet's Syndrome-Related Uveitis: A Monocentric Italian Experience 178
Orbital/ocular inflammatory involvement in VEXAS syndrome: Data from the international AIDA network VEXAS registry 177
Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study 176
Relapsing Polychondritis: an Update on Pathogenesis, Clinical Features, Diagnostic Tools, and Therapeutic Perspectives 174
Inhibition of Interleukin-1 by Canakinumab as a Successful Mono-Drug Strategy for the Treatment of Refractory Behçet's Disease: A Case Series 173
The common NOD2/CARD15 variant P268S in patients with non-infectious uveitis: a cohort study 173
The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: Clinical manifestations and long-term follow-up 172
Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome 171
Circulating intercellular adhesion molecule 1 (sICAM-1) in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) 168
Clinical profile and evolution of patients with juvenile-onset Behçet's syndrome over a 25-year period: insights from the AIDA network 167
Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in refractory Behçet disease uveitis and concomitant bladder papillary carcinoma 167
Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues 166
Treating juvenile idiopathic arthritis (JIA)-related uveitis beyond TNF-α inhibition: a narrative review 164
Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives 164
Axial spondyloarthritis in patients with recurrent fever attacks: data from the AIDA network registry for undifferentiated autoInflammatory diseases (USAIDs) 161
Diagnosis and classification of relapsing polychondritis 159
Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study 159
Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives 158
Serum amyloid-A in Behçet's disease 158
Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network 158
Idiopathic inflammatory myopathies: an update on classification and treatment with special focus on juvenile forms 157
Long-term efficacy and safety of anakinra in a patient with Behçet's disease and concomitant tuberculosis infection 157
Autoinflammatory diseases 157
The most recent advances in pathophysiology and management of tumour necrosis factor receptor-associated periodic syndrome (TRAPS): personal experience and literature review 156
The role of the F402L allele in the NLRP12-autoinflammatory disorder. Reply to: F402L variant in NLRP12 in subjects with undiagnosed periodic fevers and in healthy controls 156
Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers 154
Development and implementation of the AIDA International Registry for patients with Behçet's disease 153
Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab 153
Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis 153
Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes 152
null 150
Successful use of canakinumab in a patient with resistant Behçet's disease 148
Clinical and laboratory features associated with macrophage activation syndrome in Still’s disease: data from the international AIDA Network Still’s Disease Registry 145
Hints for Genetic and Clinical Differentiation of Adult-Onset Monogenic Autoinflammatory Diseases 145
Development and implementation of the AIDA international registry for patients with non-infectious uveitis 139
Proinflammatory Cytokines and Antiskin Autoantibodies in Patients With Inherited Epidermolysis Bullosa 137
Evolving Frontiers in the Treatment of Periodic Fever, Aphthous Stomatitis, Pharyngitis, Cervical Adenitis (PFAPA) Syndrome 137
Expanding spectrum of TNFRSF1A gene mutations among patients with idiopathic recurrent acute pericarditis 133
Ultrasound guided corticosteroids sacroiliac joint injections (SIJIs) in the management of active sacroiliitis: a real-life prospective experience 132
Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network 131
null 131
Serum immunoglobulin D levels in patients with Behçet's disease according to different clinical manifestations 131
Interleukin-1: Ariadne's Thread in Autoinflammatory and Autoimmune Disorders 128
The role of biosimilars in uveitis: Long-term real-world outcomes of the switch from original to biosimilar TNF-alpha inhibitors 128
Development and implementation of the AIDA international registry for patients with non-infectious scleritis 127
Impact of HLA-B51 on Uveitis and Retinal Vasculitis: Data from the AIDA International Network Registries on Ocular Inflammatory Disorders 127
Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: real-life experience from the international AIDA registry 127
Efficacy of anakinra in refractory Behçet's disease sacroiliitis 125
Paraneoplastic arthritides: an up-to-date case-based systematic review 124
Comparing biologic options for the management of Behcet's disease-related uveitis 124
Dry eye disease and spondyloarthritis: expanding the spectrum of systemic inflammatory disorders associated with ocular surface disease. Data from the international AIDA Network Spondyloarthritis Registry 123
Rare NLRP12 variants associated with the NLRP12-autoinflammatory disorder phenotype: an Italian case series 123
Totale 19.642
Salva come PNG Salva come JPEG
Categoria #
all - tutte 76.271
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 76.271
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.661 0 0 0 0 0 359 105 401 121 264 154 257
2021/20221.922 183 234 119 134 99 36 82 65 142 232 205 391
2022/20231.806 117 151 245 221 168 342 54 140 210 24 78 56
2023/20241.957 78 47 174 109 96 519 550 82 17 68 65 152
2024/20254.862 263 222 530 271 579 301 219 271 340 233 461 1.172
2025/20267.652 850 1.703 1.512 1.399 1.905 283 0 0 0 0 0 0
Totale 27.504